<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04246489</url>
  </required_header>
  <id_info>
    <org_study_id>MS200647_0017</org_study_id>
    <secondary_id>2019-003583-40</secondary_id>
    <nct_id>NCT04246489</nct_id>
  </id_info>
  <brief_title>Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer</brief_title>
  <official_title>A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With Advanced, Unresectable Cervical Cancer With Disease Progression During or After Platinum-Containing Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMD Serono Research &amp; Development Institute, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>EMD Serono</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate clinical efficacy and safety of bintrafusp alfa
      in participants with advanced, unresectable cervical cancer with disease progression during
      or after platinum-containing chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 16, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confirmed Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) as Evaluated by Independent Review Committee</measure>
    <time_frame>Time from first treatment to planned final assessment at approximately 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) Assessed by Independent Review Committee (IRC)</measure>
    <time_frame>Time from first treatment to planned final assessment at approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Durable Response of at Least 6 Months According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) Assessed by Independent Review Committee (IRC)</measure>
    <time_frame>Time from first treatment to planned final assessment at approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Treatment-Emergent Adverse Events (TEAEs) and Treatment-Related AEs, Including Adverse Events of Special Interest (AESIs)</measure>
    <time_frame>Time from first treatment to planned final assessment at approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) Assessed by Independent Review Committee (IRC)</measure>
    <time_frame>Time from first treatment to planned final assessment at approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) Assessed by Investigator</measure>
    <time_frame>Time from first treatment to planned final assessment at approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) Assessed by Investigator</measure>
    <time_frame>Time from first treatment to planned final assessment at approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Durable Response According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) Assessed by Investigator</measure>
    <time_frame>Time from first treatment to planned final assessment at approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) Assessed by Investigator</measure>
    <time_frame>Time from first treatment to planned final assessment at approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Time from first treatment to planned final assessment at approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of M7824 at the end of Infusion (Ceoi)</measure>
    <time_frame>Time from first treatment to planned final assessment at approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of M7824 at the end of the Dosing Interval (C trough)</measure>
    <time_frame>Time from first treatment to planned final assessment at approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity as measured by Anti-drug Antibodies Concentration</measure>
    <time_frame>Time from first treatment to planned final assessment at approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Confirmed Objective Response According to RECIST Version 1.1 Assessed by Independent Review Committee (IRC) According to Programmed Death Ligand 1 (PD-L1) Expression</measure>
    <time_frame>Time from first treatment to planned final assessment at approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) According to (RECIST Version 1.1) Assessed by an Independent Review Committee (IRC) According to Programmed Death Ligand 1 (PD-L1) Expression</measure>
    <time_frame>Time from first treatment to planned final assessment at approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Durable Response According to RECIST Version 1.1 Assessed by an Independent Review Committee (IRC) According to Programmed Death Ligand 1 (PD-L1) Expression</measure>
    <time_frame>Time from first treatment to planned final assessment at approximately 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">135</enrollment>
  <condition>Uterine Cervical Neoplasms</condition>
  <arm_group>
    <arm_group_label>Bintrafusp alfa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bintrafusp alfa</intervention_name>
    <description>Participants will receive an intravenous infusion of 1200 milligrams (mg) bintrafusp alfa once every 2 weeks until confirmed disease progression, death, unacceptable toxicity and study withdrawal.</description>
    <arm_group_label>Bintrafusp alfa</arm_group_label>
    <other_name>M7824</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants have advanced unresectable and/or metastatic cervical cancer (squamous
             cell carcinoma, adenocarcinoma, adenosquamous cell carcinoma) with disease progression
             during or after the prior platinum-containing chemotherapy:

               1. The prior platinum-containing chemotherapy may be a systemic treatment for
                  metastatic disease or in the adjuvant or neo-adjuvant setting.

               2. Participants who were intolerant to or ineligible for platinum-based chemotherapy
                  are also eligible.

               3. Participants must be na√Øve to checkpoint inhibitors

          -  Participants must have measurable disease.

          -  Participants must provide a tumor tissue sample, either from archival tissue or newly
             obtained core or excisional biopsy. If the participant received local therapy (For
             example: radiation therapy or chemoradiotherapy) after the archival tissue was taken,
             a new biopsy will be required.

          -  Participants who have Eastern Cooperative Oncology Group (ECOG) PS of 0 to 1

          -  Life expectancy greater than or equals to (&gt;=) 12 weeks as judged by the Investigator

          -  Adequate hematological, hepatic and renal function as defined in the protocol

          -  Participants with known Human Immunodeficiency Virus (HIV) infections are in general
             eligible if the following criteria are met:

               1. Clinically indicated participants must be stable on antiretroviral therapy (ART)
                  for at least 4 weeks and agree to adhere to ART.

               2. have no evidence of documented multi-drug resistance that would prevent effective
                  ART.

               3. Have an HIV viral load of &lt; 400 copies per milliliter (/mL) at Screening.

               4. Have CD4+ T-cell (CD4+) counts &gt;= 350 cells/microliter.

               5. For participants with a history of an Acquired immunodeficiency syndrome
                  (AIDS)-defining opportunistic infection within the last 12 months, participants
                  may be eligible only after consultation and agreement with the study Medical
                  Monitor.

               6. If prophylactic antimicrobial drugs are indicated, participants may still be
                  considered eligible upon agreement with the study Medical Monitor

          -  Participants with hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infections
             are in general eligible if the following criteria are met:

               1. HBV viral load below the limit of quantification and be on a stable dose of
                  antiviral therapy.

               2. Participants with a history of HCV infection should have completed curative
                  antiviral treatment and require HCV viral load below the limit of quantification.

               3. Participants on concurrent HCV treatment should have HCV below the limit of
                  quantification

          -  Other protocol defined inclusion criteria could apply

        Exclusion Criteria:

          -  Participants with active central nervous system (CNS) metastases causing clinical
             symptoms or require therapeutic intervention are excluded. Participants with a history
             of treated CNS metastases (by surgery or radiation therapy) are not eligible unless
             they have fully recovered from treatment, demonstrated no progression for at least 4
             weeks, and are not using steroids for at least 7 days prior to the start of study
             treatment.

          -  Participants with interstitial lung disease or has had a history of pneumonitis that
             has required oral or intravenous (IV) steroids

          -  Participants with significant acute or chronic infections

          -  Participants with active autoimmune disease that might deteriorate when receiving an
             immunostimulatory agent

          -  Participants with clinically significant cardiovascular/cerebrovascular disease
             including: cerebral vascular accident/stroke, myocardial infarction, unstable angina,
             congestive heart failure, or serious cardiac arrhythmia

          -  Other protocol defined exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US Medical Information</last_name>
    <phone>888-275-7376</phone>
    <email>eMediUSA@emdserono.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Communication Center</last_name>
    <phone>+49 6151 72 5200</phone>
    <email>service@emdgroup.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dignity Health Arizona General Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>jhfarley@email.arizona.edu</email>
    </contact>
    <investigator>
      <last_name>Farley John H</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Highlands Oncology Group</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>tbeck@hogonc.com</email>
    </contact>
    <investigator>
      <last_name>Joseph T Beck</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Arkansas Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202-3500</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>mjbirrer@uams.edu</email>
    </contact>
    <investigator>
      <last_name>Birrer Michael</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University Hospital and Clinics - Stanford Cancer Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>odorigo@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Oliver Dorigo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Stamford Hospital</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>sdelprete@stamhealth.org</email>
    </contact>
    <investigator>
      <last_name>Salvatore A Del Prete</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center Research Institute, Inc. - University of Kansas Cancer Center/Bloch Pavilion</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ajewell@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Andrea D Jewell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>susana_campos@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Susana M Campos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>jwallbil@med.wayne.edu</email>
    </contact>
    <investigator>
      <last_name>John Wallbillich</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>mezeiklara62@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Mutch David G</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89074</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>fadi.braiteh@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Fadi S Braiteh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center PARTNER</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>donna.mcnamara@hackensackmeridian.org</email>
    </contact>
    <investigator>
      <last_name>Donna McNamara</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwell Health, Inc. PRIME</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>vjohn@northwell.edu</email>
    </contact>
    <investigator>
      <last_name>John Veena</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>kyic@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Kyi Chrisann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC Health Clinical Trials Office</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>amanda.jackson@uc.edu</email>
    </contact>
    <investigator>
      <last_name>Amanda L Jackson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp;amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>degeest@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Koenraad De Geest</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The West Clinic</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>aelnaggar@westclinic.com</email>
    </contact>
    <investigator>
      <last_name>ElNaggar Adam C</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SCRI - Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ehamilton@tnonc.com</email>
    </contact>
    <investigator>
      <last_name>Hamilton Erika P</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>david.miller@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>David S Miller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto de Oncolog√≠a de Rosario</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>luisfein@institutodeoncologia.com</email>
    </contact>
    <investigator>
      <last_name>Luis Enrique Fein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanatorio El Parque</name>
      <address>
        <city>Salta</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>miguelangelescudero53@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Miguel Angel Escudero</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Medico San Roque S.R.L.</name>
      <address>
        <city>Tucuman</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>josezarba@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Juan Jose Zarba</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Calvary Mater Newcastle</name>
      <address>
        <city>Waratah</city>
        <state>New South Wales</state>
        <zip>2298</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>janine.lombard@calvarymater.org.au</email>
    </contact>
    <investigator>
      <last_name>Lombard Janine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>bo.gao@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Gao Bo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research Limited</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>tarek.meniawy@health.wa.gov.au</email>
    </contact>
    <investigator>
      <last_name>Tarek Meniawy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre-East Melbourne</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>linda.mileshkin@petermac.org</email>
    </contact>
    <investigator>
      <last_name>Linda R Mileshkin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>jean-francois.baurain@uclouvain.be</email>
    </contact>
    <investigator>
      <last_name>Jean-Fran√ßois Baurain</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent - Pneumology</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>hannelore.denys@ugent.be</email>
    </contact>
    <investigator>
      <last_name>Hannelore Denys</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Groeninge - Campus Kennedylaan - account 2</name>
      <address>
        <city>Kortrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>philip.debruyne@azgroeninge.be</email>
    </contact>
    <investigator>
      <last_name>Philip Debruyne</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Ardenne - Pharmacie</name>
      <address>
        <city>Libramont</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>frederic.forget@vivalia.be</email>
    </contact>
    <investigator>
      <last_name>Frederic Forget</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Ardenne - Pharmacie</name>
      <address>
        <city>Libramont</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>frederic.forget@vivalia.be</email>
    </contact>
    <investigator>
      <last_name>Forget Frederic</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Sart Tilman</name>
      <address>
        <city>Li√®ge</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>christine.gennigens@chu.ulg.ac.be</email>
    </contact>
    <investigator>
      <last_name>Gennigens Christine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Pellenberg</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>toon.vangorp@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Toon Van Gorp</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GZA Ziekenhuizen - Campus Sint-Augustinus</name>
      <address>
        <city>Wilrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>luc.dirix@gza.be</email>
    </contact>
    <investigator>
      <last_name>Luc D Dirix</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HGB - Hospital Giovanni Battista - M√£e de Deus Center - Centro de Pesquisa Cl√≠nica - Instituto do C√¢ncer</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>chrisopp.pesquisa@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Christina Pimentel Oppermann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cl√≠nica de Pesquisas e Centro de Estudos em Oncologia Ginecol√≥gica e Mam√°ria Ltda.</name>
      <address>
        <city>S√£o Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>robertohegg@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Roberto Hegg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IBCC - Instituto Brasileiro de Controle do C√¢ncer</name>
      <address>
        <city>S√£o Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>lilianarruda@ibcc.org.br</email>
    </contact>
    <investigator>
      <last_name>Lilian Arruda do Rego Barros</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICESP - Instituto do C√¢ncer do Estado de S√£o Paulo Octavio Frias de Oliveira</name>
      <address>
        <city>S√£o Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>maria.pilardiz@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Maria Del Pilar Estevez Diz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chongqing Cancer Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>qizhou9128@163.com</email>
    </contact>
    <investigator>
      <last_name>Qi Zhou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Union Hospital Tongji Medical College Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>lgl6714@163.com</email>
    </contact>
    <investigator>
      <last_name>Guiling Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Cancer Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>docwuxh@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Xiaohua Wu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University, Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>jhongl@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Jihong Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <state>Alpes Maritimes</state>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>philippe.follana@nice.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Follana Philippe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Canc√©rologie de Strasbourg Europe - ICANS - Service d'oncologie m√©dicale</name>
      <address>
        <city>Strasbourg</city>
        <state>Bas Rhin</state>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>j-emmanuel.kurtz@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Kurtz Jean-Emmanuel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CARIO - Centre Armoricain de Radioth√©rapie, Imagerie m√©dicale et Oncologie</name>
      <address>
        <city>Pl√©rin</city>
        <state>Cotes d'Armor</state>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ac.hardy@cario-sante.fr</email>
    </contact>
    <investigator>
      <last_name>Bessard Anne-Claire Hardy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Oscar lambret</name>
      <address>
        <city>Lille</city>
        <state>Nord</state>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>c-abdeddaim@o-lambret.fr</email>
    </contact>
    <investigator>
      <last_name>Abdeddaim Cyril</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Bergoni√©</name>
      <address>
        <city>Bordeaux cedex</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>a.floquet@bordeaux.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Anne Floquet</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre L√©on B√©rard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>isabelle.ray-coquard@lyon.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle Ray-Coquard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot - Service d'h√©matologie et Oncologie M√©dicale</name>
      <address>
        <city>Marne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>aude-marie.savoye@reims.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Aude-Marie Savoye</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H√¥pital Cochin - Hematologie et Oncologie M√©dicale</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>jerome.alexandre@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>J√©r√¥me Alexandre</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud - service d'oncologie medicale</name>
      <address>
        <city>Pierre Benite cedex</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>julien.peron@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Julien Peron</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICO - Site Ren√© Gauducheau</name>
      <address>
        <city>Saint Herblain</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>dominique.berton@ico.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Dominique Berton-Rigaud</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orszagos Onkologiai Intezet - Nogyogyaszati Osztaly</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>bagameria@t-email.hu</email>
    </contact>
    <investigator>
      <last_name>Andrea Bagameri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem - Szuleszeti es Nogyogyaszati Klinika</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>rudolflampe@msn.com</email>
    </contact>
    <investigator>
      <last_name>Rudolf Lampe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bacs-Kiskun Megyei Korhaz - Onkoradiologia</name>
      <address>
        <city>Kecskemet</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>horvathzso@kmk.hu</email>
    </contact>
    <investigator>
      <last_name>Zsolt Horvath</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SzSzB Megyei Korhazak es Egyetemi Oktatokorhaz - Onkoradiologia</name>
      <address>
        <city>Nyiregyhaza</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Mezei Klara</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NHO Kyushu Cancer Center - Dept of Gynecology</name>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka-Ken</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>kenzo@med.kyushu-u.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Sonoda Kenzo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital, University of the Ryukyus - Dept of Obstetrics/Gynecology</name>
      <address>
        <city>Nakagami-gun</city>
        <state>Okinawa-Ken</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>lastnamefirstname@email.jp</email>
    </contact>
    <investigator>
      <last_name>Aoki Yoichi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Osaka International Cancer Institute - Dept of Gynecology</name>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka-Fu</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>kamiura-sh@mc.pref.osaka.jp</email>
    </contact>
    <investigator>
      <last_name>Shoji Kamiura</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saitama Medical University International Medical Center - Dept of Gynecology/Oncology</name>
      <address>
        <city>Hidaka-shi</city>
        <state>Saitama-Ken</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>lastnamefirstname@email.jp</email>
    </contact>
    <investigator>
      <last_name>Kosei Hasegawa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital - Dept of Mammary Gland/Oncology</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo-To</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>kyonemor@ncc.go.jp</email>
    </contact>
    <investigator>
      <last_name>Yonemori Kan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Institute Hospital of JFCR - Dept of Gynecology</name>
      <address>
        <city>Koto-ku</city>
        <state>Tokyo-To</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>mayu.yunokawa@jfcr.or.jp</email>
    </contact>
    <investigator>
      <last_name>Mayu Yunokawa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jikei University Hospital - Dept of Gynecology</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo-To</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>aikou7000@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Aiko Okamoto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kurume University Hospital - Dept of Gynecology</name>
      <address>
        <city>Kurume-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>shinshin@med.kurume-u.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Shin Nishio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NHO Hokkaido Cancer Center - Dept of Gynecology</name>
      <address>
        <city>Sapporo-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>kato.hidenori.cy@mail.hosp.go.jp</email>
    </contact>
    <investigator>
      <last_name>Hidenori Kato</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>gynlim@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Myong Cheol Lim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>amcymkim@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Yong-Man Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>bksong.kim@samsung.com</email>
    </contact>
    <investigator>
      <last_name>Byoung-Gie Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>kjwksh@snu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Jae-Weon Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>jungyunlee@yuhs.ac</email>
    </contact>
    <investigator>
      <last_name>Jung-Yun Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>drchang@ajou.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Suk-Joon Chang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LLC Evimed</name>
      <address>
        <city>Chelyabinsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>gladkovoa@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Oleg A Gladkov</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SBIH &quot; Clinical Oncological Dispensary&quot; - Location</name>
      <address>
        <city>Krasnodar</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>best.makarova@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Yulia M Makarova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BHI of Omsk region &quot;Clinical Oncology Dispensary&quot;</name>
      <address>
        <city>Omsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>mvdvorkin@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Mikhail V Dvorkin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LLC &quot;ClinicaUZI4D&quot;</name>
      <address>
        <city>Pyatigorsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>dashavita@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Daria V Saenko</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pavlov First Saint Petersburg State Medical University - Research Institute of Pulmunology</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>orloff-sv@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Sergey V Orlov</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>FBI &quot;Scientific Research Institute of Oncology n. a. N. N. Petrov&quot;</name>
      <address>
        <city>Saint-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>a1.5@icloud.com</email>
    </contact>
    <investigator>
      <last_name>Poltoratsky Artem N</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICO l¬¥Hospitalet - Hospital Duran i Reynals</name>
      <address>
        <city>L¬¥Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>bpardo@iconcologia.net</email>
    </contact>
    <investigator>
      <last_name>Beatriz Pardo Burdalo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial de Barcelona - Servicio de Oncologia</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>lgaba@clinic.cat</email>
    </contact>
    <investigator>
      <last_name>Garcia Lydia Gaba</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron - Dept of Oncology</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>aoaknin@vhio.net</email>
    </contact>
    <investigator>
      <last_name>Ana Oaknin Benzaquen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICO Girona - Hospital Doctor Josep Trueta - Servicio de Oncologia Medica</name>
      <address>
        <city>Girona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>mpbarretina@iconcologia.net</email>
    </contact>
    <investigator>
      <last_name>Pilar Barretina Ginesta</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra (MAD) - Oncology Service</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>agonzalezma@unav.es</email>
    </contact>
    <investigator>
      <last_name>Antonio Gonzalez Martin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre - Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>luigimanso@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Luis Manuel Manso Sanchez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal - Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>eva_m_guerra@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Eva Maria Guerra Alia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario de Malaga</name>
      <address>
        <city>M√°laga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>esaezl@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Lara Enrique Saez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia - Servicio de Hematologia y Oncologia Medica</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>japfidalgo@msn.com</email>
    </contact>
    <investigator>
      <last_name>Fidalgo Jose Alejandro Perez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>China</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.intrapidclinicaltrials.com/en</url>
    <description>INTR@PID Clinical Trial Program</description>
  </link>
  <link>
    <url>https://clinicaltrials.emdgroup.com/en/trial-details/?id=MS200647_0017</url>
    <description>Trial Awareness and Transparency website</description>
  </link>
  <link>
    <url>https://medical.emdserono.com/en_US/home.html</url>
    <description>US Medical Information website, Medical Resources</description>
  </link>
  <reference>
    <citation>Strauss J, Heery CR, Schlom J, Madan RA, Cao L, Kang Z, Lamping E, Mart√© JL, Donahue RN, Grenga I, Cordes L, Christensen O, Mahnke L, Helwig C, Gulley JL. Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFŒ≤, in Advanced Solid Tumors. Clin Cancer Res. 2018 Mar 15;24(6):1287-1295. doi: 10.1158/1078-0432.CCR-17-2653. Epub 2018 Jan 3.</citation>
    <PMID>29298798</PMID>
  </reference>
  <reference>
    <citation>Lan Y, Zhang D, Xu C, Hance KW, Marelli B, Qi J, Yu H, Qin G, Sircar A, Hern√°ndez VM, Jenkins MH, Fontana RE, Deshpande A, Locke G, Sabzevari H, Radvanyi L, Lo KM. Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-Œ≤. Sci Transl Med. 2018 Jan 17;10(424). pii: eaan5488. doi: 10.1126/scitranslmed.aan5488.</citation>
    <PMID>29343622</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 28, 2020</study_first_submitted>
  <study_first_submitted_qc>January 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2020</study_first_posted>
  <last_update_submitted>June 30, 2020</last_update_submitted>
  <last_update_submitted_qc>June 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>M7824</keyword>
  <keyword>INTR@PID</keyword>
  <keyword>Bintrafusp alfa</keyword>
  <keyword>programmed death-ligand 1</keyword>
  <keyword>Cervical Cancer</keyword>
  <keyword>Transforming growth factor-Œ≤ (TGF-Œ≤)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Per company policy, following approval of a new product or a new indication for an approved product in both the EU and the US, EMD Serono will share study protocols, anonymized patient level and study level data and redacted clinical study reports from clinical trials in patients with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website https://www.emdgroup.com/en/research/our-approach-to-research-and-development/healthcare/clinical-trials/commitment-responsible-data-sharing.html</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

